Tag: Continuous Glucose Monitor (CGM)
Dexcom gets clearance for long-wearing CGM
April 14, 2025HME News Staff
SAN DIEGO – Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall mean absolute relative difference (MARD) of 8%, Dexcom G7 15 Day builds on the performance of Dexcom CGM, which the company says is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range. “The approval of Dexcom G7 15 Day marks another...
Tech, cross-selling sustain supplies market
April 4, 2025Tracy Orzel
The medical supplies industry is at a turning point, driven by rising demand for home-based care and advancing technology to meet evolving patient and provider expectations. Leaders point to developments like supply chain modernization, AI-driven efficiencies and cross-category solutions as critical tools to not only propel the category forward but also address increasing costs and reduced reimbursement.
Amazon effect
Russ Hicks, senior vice president at Cardinal Health at-Home,...
Saskatchewan expands CGM coverage
April 3, 2025HME News Staff
BURNABY, B.C. – The government of Saskatchewan has expanded public coverage for continuous glucose monitoring (CGM) systems. The expansion, which now provides full coverage for CGMs for young adults ages 18 to 25 and seniors ages 65 and over, marks a significant step toward improving clinical outcomes and enhancing the quality of life for nearly 10,000 individuals living with diabetes in the province, Dexcom says. "Managing diabetes presents unique challenges for Canadians who rely on...
FDA issues warning to Dexcom
March 27, 2025HME News Staff
SAN DIEGO – Dexcom has received a warning letter from the U.S. Food and Drug Administration regarding “non-conformities” in manufacturing and quality processes after inspections of its facilities in Sad Diego and Mesa, Ariz. In a form 8-K filed with the U.S. Securities and Exchange Commission, the company said it takes the matters identified in the warning letter seriously, has already submitted several responses to Form 483 and is in the process of preparing a written response...
DMEs improve adherence, lower costs & reduce utilization, study finds
March 25, 2025HME News Staff
DALLAS – There are significant advantages for patients receiving continuous glucose monitors through DME providers compared to pharmacies, including higher adherence rates, according to a new study published in Clinical Diabetes, a peer-reviewed journal of the American Diabetes Association.
The study, supported by CCS, demonstrates that efforts to expand access to CGMs by adding pharmacy as a new channel for distribution — alongside the established DME provider channel —...
‘Now is the time to push for greater investment in CGM tech,’ report finds
March 24, 2025HME News Staff
EDINBURGH, Scotland, and SAN DIEGO – Tech, not medicine, is the future of care for Type 2 diabetes patients, according to a new report from Dexcom.
Fifty-two percent of health care professionals ranked access to continuous glucose monitors and education as having the potential to positively help people with Type 2 manage their condition in the next 10 years compared with 30% who cited better or more effective medications.
“With policymakers increasingly focused on digital...
DME providers can help physicians manage diabetes population, study finds
March 21, 2025Theresa Flaherty, Managing Editor
DALLAS – The No. 1 reason physicians cite for not prescribing a continuous glucose monitor is its complexity, a roadblock that DME providers can help clear, according to a new study from CCS.
That complexity, along with a surge in the number of diabetes patients, leaves primary care physicians and endocrinologists feeling overwhelmed and not able to keep up-to-date on technology, and, ultimately, struggling to offer enough health coaching and education to their patients. That creates...
Sequel Med Tech collaborates with Abbott
March 19, 2025HME News Staff
MANCHESTER, N.H. – Sequel Med Tech has announced that Abbott’s FreeStyle Libre 3 Plus sensor will be the first continuous glucose monitoring device to work with its twiist Automated Insulin Delivery (AID) System powered by Tidepool. The sensor will be compatible with twiist when the system is expected to launch in the second quarter of 2025. “We are thrilled to announce our collaboration with Abbott, integrating its world-leading FreeStyle Libre technology as our first CGM partner,...
Henry Schein makes advance in ‘particularly attractive’ CGM market
March 14, 2025Theresa Flaherty, Managing Editor
MELVILLE, N.Y. – The combination of Henry Schein’s distribution capabilities with Acentus’ technology expertise will pack a one-two punch as they position themselves for future growth in the competitive diabetes market, the companies say.
Henry Schein closed recently on its acquisition of the Tampa, Fla.-based Acentus, a national supplier specializing in CGMs, in a deal that broadened its portfolio of home medical supply products.
“Acentus really enhances and integrates...
Trinity Biotech zeroes in on CGM
March 13, 2025HME News Staff
DUBLIN – Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive financial advisor to support its ongoing strategic realignment, including its increased focus on continuous glucose monitoring technology. As part of this effort, Barclays is now actively assessing how the company’s existing businesses can best align with this new strategic direction....